Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|35|11|2358-2362

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.35, Iss.11, 2015-11, pp. : 2358-2362

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Real‐world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 33, Iss. 3, 2018-03 ,pp. : 710-717

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III)

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 2, 2018-02 ,pp. : 118-125

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients

By  

HEPATOLOGY, Vol. 61, Iss. 5, 2015-05 ,pp. : 1523-1532

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real‐world data from a large healthcare provider

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 2, 2018-02 ,pp. : 144-151

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1037-1046

John Wiley & Sons Inc

Access to resources Recommend Favorite